
Opinion|Videos|August 23, 2024
Evaluating MARIPOSA’s Secondary Analysis in High-Risk Advanced EGFR-Mutant NSCLC: Practical Implications
Author(s)Martin Dietrich, MD, PhD, Wade Iams, MD
Martin Dietrich, MD, PhD, discusses the secondary analysis from MARIPOSA evaluating first-line amivantamab plus lazertinib in patients with advanced EGFR-mutant NSCLC.
Advertisement
Episodes in this series

Video content above is prompted by the following:
- Briefly comment on the secondary analysis from MARIPOSA evaluating 1L amivantamab + lazertinib vs osimertinib in patients with high-risk advanced EGFR-mutant NSCLC.
- How are you using amivantamab in the 1L and 2L treatment setting?
- How do you select patients for treatment with amivantamab?
Advertisement
Related to this article

Data from the phase 1/2 ALKOVE-1 trial support the FDA approval of neladalkib in this non–small cell lung cancer population.

Alembic’s binimetinib 15-mg and 45-mg tablets, given with encorafenib, received final FDA approval for BRAF-mutant melanoma and NSCLC.

An NDA submission had been completed for zipalertinib plus chemotherapy in untreated EGFR exon 20 insertion–mutant NSCLC based on REZILIENT3 data.

A complete response letter was given to ivonescimab for patients with previously treated EGFR-mutated NSCLC.

Pembrolizumab plus SBRT produced more toxicity vs SBRT alone among patients with early-stage non–small cell lung cancer in the phase 3 KEYNOTE-867 trial.

An end-of-phase 2 meeting with the FDA supports a phase 3 development program for silevertinib in patients with locally advanced or metastatic NSCLC.

The FDA issued a Not Approvable Letter due to uncertainty around the degree of clinical benefit with Optune Mya for patients with NSCLC and brain metastases.
Advertisement
Advertisement
Trending on CancerNetwork
1
CELMoDs vs T-Cell-Redirecting Therapies at First Relapse in Relapsed/Refractory Multiple Myeloma
2
Why CAR T May Belong Before Bispecifics in Multiple Myeloma
3
How Should CAR T and Bispecifics Be Sequenced in Multiple Myeloma?
4
Applying CELMoD Class-Level and Agent-Level Evidence to Treatment Selection in Relapsed/Refractory Multiple Myeloma
5

